Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimberly Schultz

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Nanotechnology|January 10, 2013
Terahertz sensing using ferroelectric nanowiresR Herchig, Kimberly Schultz, Kevin McCash, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 20, 2021
Opportunities and challenges for applying model-informed drug development approaches to gene therapiesArtur Belov, Kimberly Schultz, Richard Forshee, et al.
Molecular Therapy Oncolytics|November 16, 2022
Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot projectMatthew Foster, Yonatan Negash, Leslie Eberhardt, et al.
Clinical Pharmacology and Therapeutics|March 7, 2022
Summary of a Public FDA Workshop: Model Informed Drug Development Approaches for Immunogenicity AssessmentsArtur A Belov, Marisabel Rodriguez Messan, Osman N Yogurtcu, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Nanotechnology|January 10, 2013
Terahertz sensing using ferroelectric nanowiresR Herchig, Kimberly Schultz, Kevin McCash, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 20, 2021
Opportunities and challenges for applying model-informed drug development approaches to gene therapiesArtur Belov, Kimberly Schultz, Richard Forshee, et al.
Molecular Therapy Oncolytics|November 16, 2022
Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot projectMatthew Foster, Yonatan Negash, Leslie Eberhardt, et al.
Clinical Pharmacology and Therapeutics|March 7, 2022
Summary of a Public FDA Workshop: Model Informed Drug Development Approaches for Immunogenicity AssessmentsArtur A Belov, Marisabel Rodriguez Messan, Osman N Yogurtcu, et al.
Pageof 1